Clinical Trials
4 trialsNCT05807126 2024-05-02
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT02686008 2020-01-13
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
Yale University
Phase 1 Withdrawn
NCT03575078 2019-09-25
ARQ761 + PARP Inhibitor in Refractory Solid Tumors
University of Texas Southwestern Medical Center
Phase 1 Withdrawn
NCT01491139 2012-05-30
ORCA
University College, London
Phase 1 Withdrawn